Journal
VACCINE
Volume 25, Issue 42, Pages 7459-7469Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.08.018
Keywords
vaccine; ricin; bioterrorism; RiVax
Categories
Funding
- NIAID NIH HHS [U01 AI056372-01, AI-056372, U01 AI056372-04, U01 AI056372-02, U01 AI056372-03, U01 AI056372] Funding Source: Medline
Ask authors/readers for more resources
Ricin is a plant toxin that is a CDC level B biothreat. Our recombinant ricin A chain vaccine (RiVax), which contains mutations in both known toxic sites, has no residual toxicity at doses at least 800 times the immunogenic dose. RiVax without adjuvant given intramuscularly (i.m.) protected mice against intraperitoneally administered ricin. Furthermore the vaccine without alum was safe and immunogenic in human volunteers. Here we describe the development of gavage and aerosol ricin challenge models in mice and demonstrate that i.m. vaccination protects mice against ricin delivered by either route. Also RiVax protects against aerosol-induced lung damage as determined by histology and lung function tests. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available